> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# City Therapeutics Prices Upsized IPO At $18 A Share, Selling All 11,111,111 Shares Itself
- URL: https://www.bullished.co/city-therapeutics-prices-upsized-ipo-at-18-a-share-selling-all-11-111-111-shares-itself-9d318bd0/
- Published: 2026-10-16T03:06:07.000Z
- Updated: 2026-11-05T20:49:12.000Z
- Description: The RNAi drug developer is set to receive about $200.0 million in gross proceeds, with Nasdaq trading under CTY due to begin Friday.
- Author: Matteo Parrino
- Tags: Deals, CTY, Industry: Healthcare, Topic: IPOs

City Therapeutics priced its upsized initial public offering at [$18.00 a share](https://www.globenewswire.com/news-release/2026/10/16/3382239/0/en/city-therapeutics-announces-pricing-of-upsized-initial-public-offering.html?ref=bullished.co) for 11,111,111 shares, the company said Thursday. It is set to receive about $200.0 million in gross proceeds before fees and expenses, and the stock is expected to begin trading on the Nasdaq Global Market under CTY on Friday.

## What the pricing announcement says

City, a clinical-stage biotech company in Cambridge, Massachusetts, is developing RNA interference (RNAi) drugs. It sells every share in the offering, so existing holders take nothing out of the base deal.

The [$18.00 price](https://www.globenewswire.com/news-release/2026/10/16/3382239/0/en/city-therapeutics-announces-pricing-of-upsized-initial-public-offering.html?ref=bullished.co) sits in the middle of the $17.00-$19.00 range marketed before pricing, and the deal was upsized. The press release does not say by how much.

Underwriters also hold a 30-day option to buy up to 1,666,666 more shares at the IPO price, less discounts and commissions. Those shares are separate from the base deal and are not part of the $200.0 million figure.

Goldman Sachs, Jefferies and Stifel are joint book-running managers. Oppenheimer is also a joint book-running manager.

## What the money backs

The proceeds go to City, not to selling shareholders, because the company is the only seller. The release says the funds are before underwriting discounts and commissions and estimated offering expenses.

City names three lead programs. CITY-FXI targets thromboembolic diseases, meaning blood clotting disorders. CITY-RBP4 targets Stargardt disease and other retinal diseases. CITY-TFR2 targets anemia associated with chronic diseases.

The company says its platform combines proprietary cityRNA triggers, which it designed to address limits of conventional RNAi approaches, with tissue-selective delivery and genetics-driven target selection.

## What to watch

Trading is due to start Friday. The offering is expected to close Monday, so the money has not yet changed hands. The registration statements were declared effective by the SEC on Thursday.

Friday brings the first Nasdaq trades in CTY, and Monday is the scheduled close of the $18.00-a-share offering.

Learn

- [IPO Lockup Period Meaning: What Insiders Can Sell, When, And Where To See It →](https://www.bullished.co/learn/ipo-lockup-period-meaning/)  
An IPO lockup bars insiders from selling shares for a set period. Learn how to find the terms, what expiration means, and how insider sales are filed.

### Sources

- [City Therapeutics Announces Pricing of Upsized Initial Public Offering](https://www.globenewswire.com/news-release/2026/10/16/3382239/0/en/city-therapeutics-announces-pricing-of-upsized-initial-public-offering.html?ref=bullished.co) — GlobeNewswire